Metformin, a cornerstone in T2DM management, has shown promise in reducing PC risk and improving outcomes [95,96,97] by lowering insulin and IGF-1 levels and activating AMP-activated protein kinase pathways, thereby inhibiting cancer cell growth [98]. The gene discussed is IGF1; the disease is type 2 diabetes mellitus.